Novavax Inc.’s lead product, the respiratory syncytial virus vaccine (RSV) ResVax, has missed its endpoints in its first Phase III trial, sending the firm’s share price tumbling by nearly 67% to close at $0.71 on NASDAQ on Feb. 28.
Top-line data show that the trial did not meet its primary objective of preventing medically significant RSV lower respiratory tract...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?